Publications by authors named "Shubhank Goyal"
Small-cell lung cancer (SCLC) is the most fatal form of lung cancer. Intratumoral heterogeneity, marked by neuroendocrine (NE) and non-neuroendocrine (non-NE) cell states, defines SCLC, but the cell-extrinsic drivers of SCLC plasticity are poorly understood. To map the landscape of SCLC tumor microenvironment (TME), we apply spatially resolved transcriptomics and quantitative mass spectrometry-based proteomics to metastatic SCLC tumors obtained via rapid autopsy.
View Article and Find Full Text PDFArticle Synopsis
- Patients with relapsed small cell lung cancer (SCLC), known for its poor prognosis, showed some improvement when the drug berzosertib was added to topotecan in a phase 2 study.
- A randomized clinical trial conducted from December 2019 to December 2022 involved 60 patients who received either topotecan alone or in combination with berzosertib, assessing their outcomes based on progression-free survival (PFS) and overall survival (OS).
- Results indicated that after a median follow-up of 21.3 months, there was no significant difference in PFS or OS between the two treatment groups, highlighting the challenge in treating relapsed SCLC.
Article Synopsis
- The study aimed to explore the combination of chemotherapy and DNA damage response (DDR) inhibitors, focusing on using tumor-targeted chemotherapy to minimize toxicities.
- A phase I trial tested sacituzumab govitecan, an antibody-drug conjugate, with the ATR inhibitor berzosertib, involving twelve patients at increasing dose levels.
- The treatment showed improved safety with no severe adverse effects, leading to favorable tumor regressions in some patients, suggesting a promising new approach for better delivering cancer therapies.